Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Clinical trial NCT06757634 · RECRUITING
Trial details
- NCT number
- NCT06757634
- Sponsor
- Celcuity Inc
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-24
- Primary completion
- 2029-03-31
- Enrollment
- 1180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.